In CML, the lncRNA HULC was shown to promote imatinib resistance by a miR-200a/c-myc/Bcl-2 ceRNA regulatory network[85]. This evidence concerns the gene HULC and chronic myelogenous leukemia, BCR-ABL1 positive.